Species differences in the transport activity for organic anions across the bile canalicular membrane.

Species differences in the transport activity mediated by canalicular multispecific organic anion transporter (cMOAT) were examined using temocaprilat, an angiotensin-converting enzyme inhibitor whose biliary excretion is mediated predominantly by cMOAT, and 2,4-dinitrophenyl-S-glutathione, a typical substrate for cMOAT, in a series of in vivo and in vitro experiments. Temocaprilat was infused to examine the biliary excretion rate at steady-state. The in vivo transport clearance values across the bile canalicular membrane, defined as the biliary excretion rate divided by the hepatic unbound concentrations, were 9.8, 39.2, 9.2, 1.1, and 0.8 ml/min/kg for mouse, rat, guinea pig, rabbit, and dog, respectively. The K(m) and V(max) values for ATP-dependent uptake of 2, 4-dinitrophenyl-S-glutathione into canalicular membrane vesicles were 15.0, 29.6, 16.1, 55.8, and 30.0 microM and 0.38, 1.90, 0.15, 0. 47, and 0.23 nmol/min/mg protein, yielding the in vitro transport clearance across the bile canalicular membrane (V(max)/K(m)) of 25.5, 64.2, 9.4, 8.4, and 7.7 for mouse, rat, guinea pig, rabbit, and dog, respectively. A close in vivo and in vitro correlation was observed among animal species for the transport clearance across the bile canalicular membrane. These results suggest that the uptake experiments with canalicular membrane vesicles can be used to quantitatively predict in vivo excretion across the bile canalicular membrane.

[1]  Y. Sugiyama,et al.  Transporters for bile acids and organic anions. , 1999, Pharmaceutical biotechnology.

[2]  D. Keppler,et al.  cDNA Cloning of the Hepatocyte Canalicular Isoform of the Multidrug Resistance Protein, cMrp, Reveals a Novel Conjugate Export Pump Deficient in Hyperbilirubinemic Mutant Rats* , 1996, The Journal of Biological Chemistry.

[3]  H. Kusuhara,et al.  The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. , 1998, Journal of pharmaceutical sciences.

[4]  N. Ballatori,et al.  Identification and characterization of high and low affinity transport systems for reduced glutathione in liver cell canalicular membranes. , 1994, The Journal of biological chemistry.

[5]  T. Ishikawa,et al.  ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. , 1990, The Journal of biological chemistry.

[6]  Y. Sugiyama,et al.  Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[7]  K. Bischoff,et al.  Interspecies correlation of plasma concentration history of methotrexate (NSC-740). , 1970, Cancer chemotherapy reports.

[8]  Y. Sugiyama,et al.  cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). , 1998, FEBS letters.

[9]  Y. Sugiyama,et al.  Glutathione S-transferases in elasmobranch liver. Molecular heterogeneity, catalytic and binding properties, and purification. , 1981, The Biochemical journal.

[10]  K C Kwan,et al.  Enterohepatic circulation of indomethacin and its role in intestinal irritation. , 1975, Biochemical pharmacology.

[11]  A. Levi,et al.  Two hepatic cytoplasmic protein fractions, Y and Z, and their possible role in the hepatic uptake of bilirubin, sulfobromophthalein, and other anions. , 1969, The Journal of clinical investigation.

[12]  D. Chatfield,et al.  Disposition and metabolism of benoxaprofen in laboratory animals and man. , 1978, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  K. Hayashi,et al.  Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. , 1990, The Journal of biological chemistry.

[14]  D. Keppler,et al.  Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. , 1994, Gastroenterology.

[15]  D. Meijer,et al.  Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. , 1995, Biochimica et biophysica acta.

[16]  P. Bosma,et al.  Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.

[17]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[18]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[19]  P. Meier,et al.  The Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver* , 1998, The Journal of Biological Chemistry.

[20]  P. Deen,et al.  Adenosine triphosphate-dependent transport of anionic conjugates by the rabbit multidrug resistance-associated protein Mrp2 expressed in insect cells. , 1998, Molecular pharmacology.

[21]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[22]  D. Keppler,et al.  Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAJ) gene in liver , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  T. Saruta,et al.  Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS‐622) in humans , 1993, Biopharmaceutics & drug disposition.

[24]  M. Müller,et al.  Molecular aspects of hepatobiliary transport. , 1997, The American journal of physiology.

[25]  Y. Sugiyama,et al.  Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. , 1998, Molecular pharmacology.

[26]  Y. Sugiyama,et al.  Primary active transport of organic anions on bile canalicular membrane in humans. , 1999, The American journal of physiology.

[27]  Y. Sugiyama,et al.  Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). , 1997, The Journal of pharmacology and experimental therapeutics.

[28]  Y. Sugiyama,et al.  cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3) 1 , 1998 .

[29]  P. Meier,et al.  Functional expression of the rat liver canalicular isoform of the multidrug resistance‐associated protein , 1997, FEBS letters.

[30]  Y. Sugiyama,et al.  Expression of a putative ATP-binding cassette region, homologous to that in multidrug resistance-associated protein (MRP), is hereditarily defective in Eisai hyperbilirubinemic rats (EHBR) , 1996 .

[31]  A. Groen,et al.  The role of mdr2 P‐glycoprotein in hepatobiliary lipid transport , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  Y. Sugiyama,et al.  Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. , 1998, The Journal of pharmacology and experimental therapeutics.

[33]  Y. Sugiyama,et al.  Functional Analysis of a Canalicular Multispecific Organic Anion Transporter Cloned from Rat Liver* , 1998, The Journal of Biological Chemistry.

[34]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[35]  M. Saxena,et al.  ATP-dependent Efflux of 2,4-Dinitrophenyl-S-glutathione , 1995, The Journal of Biological Chemistry.

[36]  Y. Sugiyama,et al.  Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. , 1997, The American journal of physiology.